Skip to main content

01-04-2016 | Colorectal cancer | Article

Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?

Clinical and Translational Oncology

Authors: P. García-Alfonso, J. Feliú, R. García-Carbonero, C. Grávalos, C. Guillén-Ponce, J. Sastre, J. García-Foncillas

Publisher: Springer International Publishing


Treatment with regorafenib has demonstrated statistically significant improvements in terms of overall survival, progression-free survival and disease control when compared with placebo in pretreated patients with metastatic colorectal cancer in two placebo-controlled, randomized, phase III trials (CORRECT and CONCUR). Similar results were observed in two open-label, single-arm studies (REBECCA and CONSIGN) performed in the real-world setting. But several authors have suggested that the benefit provided by regorafenib may not be clinically meaningful for these patients. Moreover, it has been suggested that not all subgroups of patients might benefit from regorafenib. The intention of this review is to provide an overview of the existing evidence for regorafenib in terms of efficacy, tolerability and quality of life in different subpopulations according to clinical and biological characteristics. Additionally, the magnitude of the clinical benefit provided by regorafenib to these patients has been explored and whether there are poorer outcomes in certain subpopulations.

Please log in to get access to this content

Related topics